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223Ra Therapy in Patients With Advanced Castration-Resistant
Prostate Cancer With Bone Metastases
Lessons from Daily Practice
Maarten J. van der Doelen, MD,*† Malou C.P. Kuppen, MD,* Marianne A. Jonker, PhD,‡
Niven Mehra, MD, PhD,* Marcel J.R. Janssen, MD, PhD,§
Inge M. van Oort, MD, PhD,† and Winald R. Gerritsen, MD, PhD*
Purpose: To identify pre-therapeutic variables associated with overall sur-
vival (OS) in patients treated with 223Ra.
Methods: Data from 45 CRPC patients treated with 223Ra were retrospec-
tively analyzed. All patients who received at least one 223Ra injection were
included in the study. Cox proportional hazard regression models were used
to estimate hazard ratio’s (HR) and to test for association.
Results: Twenty-one patients (47%) received six 223Ra injections and
24 patients (53%) received one to five 223Ra injections. Median OS since
start of 223Rawas 13.0 months (95% confidence interval (CI) 8.2–17.8). Pa-
tients who completed 223Ra therapy had a median OS of 19.7 months (95%
CI 14.9–24.6), while patients who received one to five 223Ra injections had
a median OS of 5.9 months (95% CI 3.8–8.1; P < 0.001).
Univariable analysis showed poor baseline ECOG performance status (PS),
baseline opioid use, lowered baseline hemoglobin, and elevated prostate-
specific antigen, alkaline phosphatase and lactate dehydrogenase (LD) levels
were significantly associated with OS. Multivariable Cox regression analysis
demonstrated that poor baseline ECOG PS (HR 10.6) and high LD levels
(HR 7.7) were pre-therapeutic variables that predicted poor OS.
Conclusions: In a multivariable Cox regression model, good baseline
ECOG PS and low LD levels were significantly associated with longer OS
in patients treated with 223Ra. These variables may be used for stratification
of CRPC patients for 223Ra therapy. Prospective studies to evaluate these
variables are warranted, to develop a nomogram to select patients properly.
In this retrospective study, predictors of overall survival in 45 metastatic
castration-resistant prostate cancer patients treated with 223Ra therapy were
evaluated. Baseline ECOG performance status and lactate dehydrogenase
levels turned out to be significant in a multivariable prediction model for
overall survival.
Key Words: prostate cancer, 223Ra, bone metastases, castration-resistant,
radiopharmaceutical
(Clin Nucl Med 2018;43: 9–16)
223R a is a registered palliative therapy for castration-resistantprostate cancer (CRPC) patientswith symptomatic bone
metastases. This radioisotope is very similar to calcium and binds se-
lectively to areas of increased bone turnover in bone metastases.
There it emits high-energy alpha particles of short range
(<100 μm; 2–10 cell layers), causing double-strand DNA breaks
leading to a cytotoxic effect on tumor cells and cells in the
tumor microenvironment.1,2
In the phase 3 ALSYMPCA trial, CRPC patients were treated
with 223Ra or placebo, either before or after docetaxel chemother-
apy.3 The outcome was a significant median overall survival (OS)
benefit of 3.6 months in favor of 223Ra over placebo. Subsequent
analyses demonstrated survival benefit of 223Ra in chemotherapy-
naïve CRPC patients as well as in post-chemotherapy CRPC pa-
tients.4 In addition, 223Ra reduced the risk of symptomatic skeletal
events and was accompanied by significant improvement of quality
of life.5,6
To date, clinical data on 223Ra in daily practice is scarce. In
the ALSYMPCA trial, 63% of CRPC patients treated with 223Ra re-
ceived six injections, whereas only 42% of the Dutch patients re-
ceived six 223Ra injections in 2016, with a median number of four
injections.3 This may indicate that real-world patients treated with
223Ra differ from those included in the ALSYMPCA trial.7
In addition, effect monitoring during 223Ra therapy is chal-
lenging. Therefore, optimal patient selection is crucial. It is impor-
tant to identify pre-therapeutic factors to estimate whether a patient
will achieve OS benefit of 223Ra. Knowledge of these factors can
lead to better patient selection and might lead to a reduction of
health care costs. The objective of this study was to evaluate real-
world data of CRPC patients treated with 223Ra, in order to deter-
mine pre-therapeutic variables that predict OS and to describe
baseline differences between patients who completed and patients
who discontinued 223Ra therapy.
PATIENTS AND METHODS
Study Design and Patient Population
CRPC patients treated with 223Ra between September 2013
andMarch 2016were retrospectively evaluated. Patients who received
at least one 223Ra injection were included in the study. There were no
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exclusion criteria. All patients continued androgen deprivation therapy
and patients were castration-resistant according to the European Asso-
ciation of Urology definition.8
The medical records of the patients were reviewed to collect
information about demographic characteristics, comorbidity, histol-
ogy, surgical procedures and medical therapies for prostate cancer,
laboratory evaluations, imaging studies, the occurrence of skeletal
related events (SREs) and survival. All patients were followed until
death or June 1, 2017.
223Ra Therapy Standard of Care
223Ra was injected intravenously every 4 weeks up to six cy-
cles according to standard of care.9 Institutional criteria for initiation
of 223Ra therapy included CRPC patients with bone metastases, no
or small (<3 cm in short-axis diameter) lymph node metastases and
no visceral metastases. Laboratory requirements were baseline abso-
lute neutrophil count >1.5 109/L and platelet count >100 109/L.
Laboratory evaluation was carried out within 60 days before 223Ra
initiation. Within 3 months prior to start of 223Ra therapy imaging
studies were performed, including a bone scintigraphy and computer
tomography (CT) of thorax and abdomen. Before every injection,
performance status (PS) was scored according to the Eastern Coop-
erative Oncology Group (ECOG) criteria. Laboratory evaluation
before every 223Ra injection included hemoglobin (Hb), platelets,
lactate dehydrogenase (LD), alkaline phosphatase (ALP) and pros-
tate specific antigen (PSA)measurements. All eligible patients were
discussed in our multidisciplinary team meeting before initiation of
223Ra therapy.
Adverse Events
Adverse events during 223Ra therapy were scored using the
CommonTerminologyCriteria for Adverse Events (CTCAE), version
4.03. SREswere defined as symptomatic fracture, radiation or surgery
to bone, or spinal cord compression.10
Biochemical and Radiological Response Evaluation
Changes in PSA and ALP were calculated from baseline to
week 12 (after three injections), from baseline to end of therapy
(approximately 1 month after the last injection) and as maximal
percentage change at any time from baseline. Patients who had
no baseline level, no follow-up measurements or received concom-
itant enzalutamide or abiraterone were excluded from biochemical
response evaluation. More than 25% decline or increase from base-
line of PSA, ALP and LD was considered to be clinically signi-
ficant, according to Prostate Cancer Working Group 3 criteria.10
Radiological evaluation was performed in patients who underwent
evaluation of soft tissues within 3 months after completion or dis-
continuation of therapy.
Statistical Methods
Survival time was defined as the time interval from date of
first 223Ra injection to the date of death. Cox proportional hazards
models were used to assess the prognostic significance of baseline
variables in univariable and multivariable analysis. A multivariable
Cox regression modelwas fitted by including variables in themodel
with a forward selection strategy based on Wald’s test at a signifi-
cance level of 0.10 at every step. In case baseline variables were
heavily skewed distributed or the proportional hazard assumption
was not likely to hold, log transformation or categorization of vari-
ables was performed.
To compare baseline characteristics between patients who
completed and discontinued 223Ra therapy, the chi-square test or
Fisher exact test was used. Statistical tests were performed two-
sided, with P values <0.05 considered statistically significant.
Survival curves for patients who completed therapy and patients
who discontinued therapy were estimated by the Kaplan–Meier
estimator. The Mantel–Cox log rank test was used to compare
the survival distributions.
Statistical analyses were performed using SPSS 22.0 (IBM®,
Armonk, NY, USA). Figures were created with SPSS andGraphPad
Prism 5.03 (GraphPad Software, Inc., La Jolla, CA, USA).
Ethics
This study was approved by the medical ethics review com-
mittee. The principles of the Helsinki Declaration were followed.
RESULTS
Patient Characteristics
Patient characteristics of the 45 CRPC patients who received
223Ra are shown in Table 1. The median number of prior registered
therapies for CRPC was 2 (range 0–4). Twenty-five patients (56%)
received prior docetaxel chemotherapy and 35 patients (78%) re-
ceived prior enzalutamide and/or abiraterone. Baseline laboratory
and imaging characteristics are described in Table 2.
Overall Survival
Thirty-eight patients (84%) had died at time of analysis. The
median OS since start of 223Ra in the whole study population was
13.0 months (95% CI 8.2–17.8). Univariable analysis showed that
baseline ECOG PS, baseline opioid use and baseline hemoglobin,
PSA, ALP and LD levels were variables significantly associated
with OS (Table 3). With the multivariable analysis we found a
model that included baseline ECOG PS and baseline LD levels
(Table 4). However, the multivariable analysis was restricted to 32
subjects (71%) due to limited availability of baseline LD levels
(complete case analysis). When the baseline LD level variable
was left out from analysis, 41 subjects (91%) were included in
the analysis and baseline ECOG PS, baseline hemoglobin level
and opioid use were selected in multivariable analysis (hazard
ratios 2.6 (95% CI 1.1–5.8); 0.8 (95% CI 0.6–1.0) and 2.2 (95%
CI 1.0–4.7), respectively).
The Number of Injections
Twenty-one (47%) patients received all six injections. The
median number of injections was five. Four patients (9%) received
one or two injections, seven patients (16%) received three injec-
tions, four patients (9%) received four injections and nine patients
(20%) received five injections. We found significant differences be-
tween patients who received one to five injections and those who
completed therapy regarding baseline LD levels, baseline opioid
use and prior use of abiraterone or enzalutamide (Tables 1 and 2).
Patients who completed 223Ra therapy had a median OS of
19.7 months (95% CI 14.9–24.6), while patients who received
one to five 223Ra injections had a median OS of 5.9 months
(95% CI 3.8–8.1; P < 0.001) (Fig. 1). This significant finding in
survival was substantiated by the OS difference between five (n = 9)
and six 223Ra injections (7.3 vs 19.7 months, P < 0.01).
Adverse Events
Persistent hematologic toxicity was the reason to discontinue
223Ra therapy in nine of 24 patients (38%; pancytopenia in four pa-
tients, thrombocytopenia in three patients, anemia in two patients).
No grade 3–4 non-hematologic adverse events occurred during and
after therapy.
At baseline, 33 patients (73%) had grade 1 anemia and five
patients (11%) had grade 2 anemia. Only one patient with initial
grade 2 anemia completed therapy. During therapy, 16 patients
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received red blood cell transfusion. Seventy-five percent of these
patients did not complete therapy and 81% of these patients had re-
ceived two or more prior CRPC therapies. OS was significantly
worsewhen compared to patients who did not need blood cell trans-
fusion (8 versus 14 months). At any time during therapy, grade 1
thrombocytopenia occurred in 11 patients (24%) and grade 2
TABLE 3. Univariate Analysis of Overall Survival
n Median OS (months) HR 95% CI P
Age (years) 45 13.0 1.01 0.97–1.06 0.59
ECOG, categorical <0.01
ECOG 0 21 19.7 1.00
ECOG 1 15 5.9 3.35 1.59–7.06 <0.01
ECOG 2–3 8 7.3 4.15 1.66–10.33 <0.01
Opioid use
No 25 15.7 1.00
Yes 20 5.9 2.00 1.05–3.81 0.03
Initial tumor Gleason score
GS ≤7 18 11.0 1.00
GS 8–10 27 13.6 0.88 0.46–1.69 0.71
Extent of disease 0.16
6–20 metastases 9 17.0 1.00
>20 metastases 28 13.5 1.32 0.56–3.13 0.52
Superscan* 8 7.9 2.62 0.92–7.49 0.07
Prior chemotherapy
No 20 15.7 1.00
Yes 25 8.9 1.77 0.90–3.49 0.10
Prior abiraterone or enzalutamide
No 10 8.6 1.00
Yes 35 13.0 1.74 0.72–4.19 0.22
Number of prior CRPC therapies
0–1 18 14.3 1.00
≥2 27 10.0 1.47 0.75–2.85 0.26
Number of prior CRPC therapies 0.24
0 6 5.1 1.00
1 12 14.3 1.24 0.38–4.06 0.72
2 10 8.9 1.10 0.32–3.77 0.88
3 9 11.0 1.80 0.55–5.92 0.33
4 8 6.0 3.07 0.87–10.80 0.08
Hemoglobin (g/dL), continuous 45 13.0 0.74 0.58–0.93 <0.01
Hemoglobin (g/dL), dichotomized
Hb > 10 40 13.6 1.00
Hb ≤ 10 5 5.7 3.81 1.39–10.38 <0.01
Platelet count, continuous 45 13.0 1.00 1.00–1.00 0.21
ANC, continuous 36 11.0 0.98 0.84–1.14 0.78
NLR, continuous 35 11.0 1.08 0.94–1.24 0.30
Log PSA 44 13.0 1.23 1.03–1.48 0.03
Log ALP 43 12.2 1.66 1.16–2.35 <0.01
ALP, dichotomized (U/L)
ALP < 115 16 15.7 1.00
ALP ≥ 115 27 8.6 2.16 1.05–4.44 0.04
Log LD (U/L) 33 11.0 7.39 2.54–21.54 <0.01
LD, dichotomized (U/L)
LD < 250 20 15.7 1.00
LD ≥ 250 13 5.9 2.78 1.23–6.30 0.01
Albumin (g/L) 33 13.6 0.96 0.87–1.05 0.34
Bold = P < 0.05.
*Superscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity.
ALP indicates alkaline phosphatase; ANC, absolute neutrophil count; CI, confidence interval; CRPC, castration-resistant prostate cancer; ECOG, Eastern Cooperative Oncology
Group; GS, Gleason score; Hb, hemoglobin; HR, hazard ratio; LD, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; PSA, prostate-specific antigen.
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(2%) or 3 (2%) occurred in one patient each. Flare-up of pain imme-
diately after 223Ra administration occurred in 16 patients (36%) at
any time during therapy.
Physical health deteriorationwas the reason to stop therapy in
six (25%) patients. Five of these six patients had a baseline ECOG
PS of 1 (33%) or 2 (50%).
During therapy, 14 SREs were reported in 11 patients (24%).
In seven patients spinal cord compression occurred, which was
treated by external beam radiotherapy (EBRT) plus dexamethasone.
In two patients a pathological fracture occurred; these patients both
discontinued therapy. Additionally, three patients underwent EBRT
because of increase of pain at a solitary lesion.
Biochemical Response Evaluation
Figure 2 shows PSA and ALP dynamics in patients treated
with 223Ra monotherapy. Significant increase of PSAwas observed
in 65% of patients after three injections. Significant decrease of
ALP was found in 53% of patients after three injections. All of
the patients with PSA decrease showed remarkable ALP decrease
(range 23%–75%). ALP at end of therapy was significantly lower
in patients who completed therapy when compared to patients
who discontinued therapy (P < 0.01).
Radiological Response Evaluation
In retrospect, four patients (10%) had small visceral metasta-
ses in either liver (n = 2) or lungs (n = 2) prior to start of 223Ra ther-
apy. The two patients with lung metastases completed 223Ra
therapy, while both patients with liver metastases discontinued ther-
apy after the fourth injection.
After 223Ra therapy, 20 patients (44%) underwent evaluation
of lymph nodes and soft tissues. Radiological evaluation was
mainly performed in patients that completed therapy (90% versus
38%). New lymph node enlargement (≥15 mm in the short axis)
was shown in 17% of patients. New visceral metastases to liver, lung,
spleen and/or brainwere found in 41%of patients. All of these patients
were heavily pretreated. Among the 24 patients who discontinued
therapy, radiological disease progression was the main reason to stop
therapy in five (21%) patients.
Therapies After 223Ra Therapy
In patients who discontinued 223Ra therapy, best supportive
care (67%) or a second-generation anti-hormonal agent (33%) was
started. In patients who completed 223Ra therapy, subsequent therapy
was a second-generation anti-hormonal agent in 15 patients (71%).
Two patients (10%) received docetaxel without any toxicity during
chemotherapy and three patients (14%) received best supportive care
after completion of 223Ra therapy.
DISCUSSION
Overall Survival
Median OS in this cohort was 13.0 months, which is similar
to the ALSYMPCA trial.3 Multivariable analysis selected baseline
ECOG PS and LD levels to be significantly associated with OS in
this study. The post hoc multivariable analysis of the ALSYMPCA
trial also selected baseline ECOG PS and LD were correlated with
OS. In addition, that analysis identified albumin level, total ALP,
PSA and age to be correlated with OS as well.11 The analysis of
TABLE 4. Multivariable Analysis of Overall Survival
n HR 95% CI P
Prior abiraterone or enzalutamide 32
No 9 1.00
Yes 23 2.38 0.91–6.23 0.08
ECOG, categorical 32 <0.01
ECOG 0 17 1.00
ECOG 1 9 10.62 3.07–36.73 <0.01
ECOG 2–3 6 5.67 1.74–18.47 <0.01
Log LD 32 7.67 1.75–33.53 <0.01
Bold = P < 0.05.
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR,
hazard ratio; LD, lactate dehydrogenase.
FIGURE 1. Kaplan–Meier curve of overall survival (OS), stratified by number of injections received (1–5 versus 6 injections).
Log-rank P value < 0.001.
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the early access program demonstrated median OS was longer for
patients with low baseline ALP levels, Hb > 10.0 g/dL, ECOG per-
formance score of 0, no reported baseline pain, concomitant use of
abiraterone or enzalutamide and concomitant use of denosumab.12
Recent retrospective analyses stated low baseline ALP levels, no
or less prior therapies, and a low number of bonemetastases are cor-
related with better OS.13–15 In fact, all of these pre-therapeutic var-
iables reflect less advanced disease. These findings, and the fact that
the prevalence of visceral metastases increases towards advanced
disease stage, seem to underline the need for early application of
223Ra in CRPC patients.16
Number of Injections
Remarkable difference in OS between patients who com-
pleted and discontinued 223Ra therapy was found. Recently, several
retrospective studies described significant associations between the
received number of 223Ra injections and OS.13,14,17 However, these
results have to be interpreted with caution, due to immortal time
bias.18 After all, patients must survive sufficiently long to complete
223Ra therapy. In addition, the question remains whether the com-
pletion of therapy is the cause of the difference in OS, rather than
better patient selection.
Response Evaluation
At week 12 of therapy, ≥25% reduction in PSAwas found in
6% of patients. This low PSA response rate is comparable to findings
in the ALSYMPCA trial and the early access program.3,12 According
to the proportional treatment effect analysis of the ALSYMPCA trial,
ALP decrease at 12 weeks from baseline was found to be the best in-
dicator for risk of death, but accounted only for 34% of the survival
benefit from 223Ra treatment.11 This indicates response evaluation of
223Ra should consist of more than biochemical evaluation alone.
There is a clinical need for reliable biomarkers for optimal patient se-
lection and effect monitoring during 223Ra therapy.
In this study, only 44% of patients underwent CT within
3 months after termination of 223Ra therapy. New visceral metasta-
ses were found in 41% of the patients. This percentage may be over-
estimated due to selection of patients for radiological evaluation.
However, a recent study described radiological extraskeletal disease
progression in even 46% of patients.19 Advanced imaging tech-
niques, such as 68Ga-PSMA-11 PET/CT, may be helpful to rule out
extraskeletal disease prior to 223Ra therapy initiation and was also de-
scribed to be useful as a gatekeeper during 223Ra therapy.20–23
Study Limitations
The impact of this study is limited by its retrospective single-
center design and relative small sample size. It is, therefore, susceptible
to recall and interpretation bias. The sample size restricted extensive
regression analysis. However, this real world study was able to dis-
criminate important baseline variables which are associated with
OS. These results were similar to outcomes of other studies.
Learning Curve
Our team experienced a learning curve towards optimal pa-
tient selection for 223Ra therapy. In 2014, only 27% of the patients
completed therapy. In 2016, 65% of the patients completed therapy.
FIGURE 2. Waterfall plots showing percentages change in alkaline phosphatase (ALP) and prostate-specific antigen (PSA).
Percentage change in ALP frombaseline to week 12, from baseline to end of therapy andmaximumpercentage change in ALP
from baseline during therapy (A–C). Percentage change in PSA from baseline to week 12, from baseline to end of therapy and
maximum percentage change in PSA from baseline during therapy (D–F).
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Nationwide, only 42% of the Dutch patients completed therapy in
2016. According to recent recommendations and our experience,
patients should be discussed in a multidisciplinary tumor board with
presence of a nuclear physician before start of therapy.8,24 In addi-
tion, all patients must be radiologically evaluated before and after
therapy. During therapy, additional imaging may be considered in
case of extraordinary elevation of tumor markers, in order to rule
out extraskeletal disease.19
CONCLUSIONS
In CRPC patients treated with 223Ra, we found a remarkable
difference in OS between patients who discontinued and completed
therapy. Baseline ECOG PS and LD levels were selected in a mul-
tivariable Cox regression model to predict OS. Prospective obser-
vational multicenter studies with larger patient populations are
needed to confirm our findings and to develop a nomogram to select
patients properly.
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